Island Pharmaceuticals Limited, a drug research and repurposing company, focuses on the development of preventative or therapeutic drugs for viral infections in Australia and the United States of America. Its lead product candidate is ISLA-101, a drug for the prevention and treatment of dengue fever and other mosquito borne diseases. The company has a collaboration agreement with Monash University and National Cancer Institute IND. It also has a cooperative research and development agreement with the U.S. Army, Island in preparation for its Phase 2a/b clinical study for ISLA-101. Island Pharmaceuticals Limited was founded in 2017 and is based in Camberwell, Australia.
Metrics to compare | ILA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipILAPeersSector | |
---|---|---|---|---|
P/E Ratio | −16.0x | −3.3x | −0.5x | |
PEG Ratio | −1.89 | −0.01 | 0.00 | |
Price/Book | 13.3x | 1.5x | 2.6x | |
Price / LTM Sales | 130.0x | 8.1x | 3.3x | |
Upside (Analyst Target) | 84.5% | 223.8% | 43.4% | |
Fair Value Upside | Unlock | 26.2% | 7.1% | Unlock |